These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31704470)

  • 1. Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):351-357. PubMed ID: 31704470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
    He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
    [No Abstract]   [Full Text] [Related]  

  • 6. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
    Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
    Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
    Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
    Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
    Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion.
    Qi L; Huang X; He C; Ji D; Li F
    J Int Med Res; 2021 Dec; 49(12):3000605211063292. PubMed ID: 34918995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
    Mo XD; Hong SD; Zhao YL; Jiang EL; Chen J; Xu Y; Sun ZM; Zhang WJ; Liu QF; Liu DH; Wan DM; Mo WJ; Ren HY; Yang T; Huang H; Zhang X; Wang XN; Song XM; Gao SJ; Wang X; Chen Y; Xu B; Jiang M; Huang XB; Li X; Zhang HY; Wang HT; Wang Z; Niu T; Wang JS; Xia LH; Liu XD; Li F; Zhou F; Lang T; Hu J; Wu SJ; Huang XJ
    Am J Hematol; 2022 Apr; 97(4):458-469. PubMed ID: 35064928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
    Meng G; Wang J; Wang X; Wang Y; Wang Z
    Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study.
    Wu Y; Sun G; Tang B; Song K; Cheng Y; Tu M; Zhu X
    Transplant Cell Ther; 2024 Sep; 30(9):916.e1-916.e12. PubMed ID: 38971463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
    Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q
    J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.
    Tan Y; Xiao H; Wu D; Luo Y; Lan J; Liu Q; Yu K; Shi J; He J; Zheng W; Lai X; Zhu Y; Du K; Ye Y; Zhao Y; Zheng G; Hu Y; Han X; Zheng Y; Wei G; Cai Z; Huang H
    Oncoimmunology; 2017; 6(3):e1277307. PubMed ID: 28405499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation].
    Liu WB; Sun YQ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):106-111. PubMed ID: 32135625
    [No Abstract]   [Full Text] [Related]  

  • 17. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
    Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
    Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study.
    Verbeek AB; Jansen SA; von Asmuth EGJ; Lankester AC; Bresters D; Bierings M; Mohseny AB; Lindemans CA; Buddingh EP
    Transplant Cell Ther; 2022 Sep; 28(9):600.e1-600.e9. PubMed ID: 35717003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of CD8
    Zhang AD; Wei XX; Guo JY; Jin XS; Zhang LL; Li F; Gu ZY; Bo J; Dou LP; Liu DH; Li M; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):896-905. PubMed ID: 38926986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.